Induction Chemotherapy as a Predictor for Definitive Treatment in Bulky Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Schedule More Suited to Sub Himalayan Region
Journal Title: Journal of Cancer and Tumor International - Year 2017, Vol 6, Issue 4
Abstract
Purpose: Use of induction chemotherapy (IC) as a predictor for definitive treatment in bulky locally advanced head and neck cancer (LA HNSCC) patients, who are not feasible for any upfront radical treatment in sub-Himalayan population. Materials and Methods: 33 patients (stage IVA and IVB, T4, N3) LA HNSCC were treated with induction chemotherapy (TP) from April 2013 to August 2015. All patients were considered inoperable or not feasible for upfront radical treatment and Eastern Cooperative Oncology Group (ECOG) Performance status was ≤ 2. All patients were reviewed at multidisciplinary tumor board and considered for initial 3 cycles of induction chemotherapy in view of bulky stage IV LAHNSCC. Subsequent Radical (CTRT or Sx → CT RT) or palliative treatment was decided by tumor board after response assessment of NACT. The Statistical Package for the Social Sciences software (SPSS version 16.0) was used for analysis. The response rate, toxicity (accordance with CTCAE vs. 4.02), completion rate of radical treatment post NACT and overall survival was reported. Results: Median follow up was 22 months (18-26 months). After 3 cycles of IC, 20 patients (60.66%) underwent radical treatment and remaining 13 patients (39.33%) were treated with palliative treatment. Overall grade 2-3 toxicity was seen in 12 patients. No toxicity related mortality was noted. The completion rate of radical treatment post IC was 93.5%. The median OS was 18 month ((95% CI 9.00 to 31.00). Total 16 Patients are alive, in which 11 is disease free. Twelve patients expired and 5 patients were lost to follow up. Conclusion: Our present experience suggests that neoadjuvant chemotherapy with doublet regime is reasonably well tolerated and feasible in limited resource setting of patients with locally advanced disease who are not fit for upfront radical treatment.
Authors and Affiliations
Vipul Nautiyal, Saurabh Bansal, Meenu Gupta, Manisa Pattanayak, Deep S. Pruthi, Mushtaq Ahmad, Sunil Saini
Keywords
Related Articles
- EP ID EP309130
- DOI 10.9734/JCTI/2017/38073
- Views 93
- Downloads 0
Granulocytic Sarcoma of Ovary Associated with Chronic Myelogenous Leukaemia Mimicking Carcinoma: A Rare Case Report
Granulocytic sarcoma is a rare haematological neoplasm due to extramedullary leukemic deposits. Granulocytic Sarcoma of ovary is even rare associated with chronic myeloid leukaemia and responds to imatinib treatment. A s...
Chemotherapy Induced Skin Toxicities and Review of Literature
Chemotherapeutic drugs have proven efficacy in the treatment of most of the cancers. Chemotherapy induced side effects are commonly seen in clinical oncology. Development of new chemotherapeutic drugs and various new pro...
Immunotherapy as a Future Treatment for Relapsed and Metastatic Primary Pulmonary Sarcomas
Primary pulmonary sarcomas (PPS) are aggressive tumors that are ideally treated with complete surgical resection, although seldom possible. Chemotherapy and radiotherapy have proven to be inadequate as second-line in the...
Long Time Survival in Small Cell Carcinoma of the Bladder: A Case Report
Small cell carcinoma of the bladder only accounts for 0,35 – 1% of all bladder cancers. It is a rare, but aggressive tumor. As for other types of bladder cancer, first symptoms are most often painless hematuria [1,2]. Th...
Primary Breast Lymphoma: A Study of 9 Cases
Aim: Non-Hodgkin's primary lymphoma of the breast is rare. These tumors represent 0.04 to 0.52% of malignant breast pathology, 2.2% of extranodal lymphoma and 0.4% of all non-Hodgkin’s lymphoma. Clinical and radiological...